1. Generics Bulletin
  2. >>Podcasts

The Generics Bulletin Podcast: Stelara Biosimilar Launches In The US

Editors Discuss The Latest Developments For Ustekinumab Rivals

 
• By Dave Wallace

In the wake of multiple ustekinumab biosimilar rivals to Stelara launching in the US at the end of February, Generics Bulletin’s editors discuss the market dynamics and the latest key developments.

Generic Bulletin Podcast

This edition of the Generics Bulletin podcast sees executive editor Dave Wallace and deputy editor Dean Rudge discuss the latest developments around Stelara (ustekinumab) biosimilars in the US.

Last year, Generics Bulletin looked ahead to the imminent US onset of biosimilar competition to Stelara to ask whether it would be “groundhog day” for the industry after experiences with Humira (adalimumab) biosimilars in 2023.

At the end of 2024, we took a look at the approved contenders that were set to enter the market, before in January and February reporting on the biosimilar launches and their price discounts – as well as bringing news of a legal challenge from J&J threatening to block Sandoz’s private-label ustekinumab biosimilar.

More from Podcasts

The Generics Bulletin Podcast: Stelara Biosimilar Launches In The US

 
• By Dave Wallace

In the wake of multiple ustekinumab biosimilar rivals to Stelara launching in the US at the end of February, Generics Bulletin’s editors discuss the market dynamics and the latest key developments.

The Generics Bulletin Podcast: Highlights Of 2024

 
• By Dave Wallace

Generics Bulletin's editorial team discusses key topics from the year, including the latest rankings of the Generics Bulletin Top 50, Amgen’s surprise launch of a US Eylea biosimilar, the EU’s Urban Waste Water Treatment Directive and supply-chain issues for the off-patent sector.

More from Business

Gedeon Richter: General Medicines Unit Deserves ‘More Attention And Credit’

 
• By Dean Rudge

Gedeon Richter’s CEO has urged analysts and the firm itself to give more attention to its “unfairly neglected” General Medicines division – which includes both generics and licensed-in innovative products – during the Hungarian firm’s first-quarter earnings call.

Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches

 
• By Urtė Fultinavičiūtė

With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.

Hyloris Strikes New Deals With AFT And QliniQ Over Novel Valacyclovir Formulation

 
• By Adam Zamecnik

The Belgian value-added medicines specialist company struck two commercialization deals over its novel valacyclovir oral suspension that span three continents, marking a further milestone in the product’s development.